ANNX AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
ANNX Current Performance
1.05%
Annexon inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to ANNX
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
ANRO | Alto neuroscience inc | - | 3 | 2 | 3 | 1 | |
CGON | Cg oncology inc | - | 3 | 2 | 3 | 1 | |
FTRE | Fortrea holdings inc | - | 3 | 4 | 3 | 1 | |
MURA | Mural oncology plc | - | 3 | 2 | - | 1 | |
RVNC | Revance therapeutics inc | 3 | 4 | 2 | 3 | 1 |
- ANRO Alto neuroscience incValue -Trend 3Swing Trading 2Whale Interest 3Dividend 1See more
ANNX Profile
Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. It has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.